Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data.
Ontology highlight
ABSTRACT: Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database).
SUBMITTER: Shin KH
PROVIDER: S-EPMC10275435 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
ACCESS DATA